June Almenoff, MD, PhD
Dr. June Almenoff is an accomplished biopharma executive with 20 years of senior leadership experience in the pharmaceutical industry. She recently served as President and Chief Marketing Officer of Furiex Pharmaceuticals, which was acquired by Actavis plc (now Allergan) for $1.2B. Furiex developed eluxadoline (Viberzi®), which was recently approved in both the United States and Europe. Prior to joining Furiex, Dr. Almenoff was at GlaxoSmithKline (GSK) for 12 years, where she held various positions of increasing responsibility. She was a Vice President in the Clinical Safety Organization, chaired a PhRMA-FDA working group, and worked in the area of scientific licensing. Dr. Almenoff also led the development of pioneering systems for minimizing risk in drug development, which have been widely adopted by industry and regulators.
Dr. Almenoff is currently an independent biopharma consultant and Board Director. She is Executive Chair of RDD Pharma and a Director of TiGenix NV (TIG), and Ohr Pharmaceutical (OHRP). She serves on the advisory boards of several private companies and the investment advisory board of the Harrington Discovery Institute.
Dr. Almenoff graduated from the MD-PhD program at the Icahn School of Medicine at Mount Sinai. She completed her medical training at Stanford University Medical Center and served on the faculty of Duke University School of Medicine.